Cargando…

Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status

Several endocrine therapies are currently available for the treatment of estrogen receptor (ER) positive breast cancer, but the clinical benefit of these agents is limited by endocrine therapy drug resistance. A common mechanism of endocrine therapy resistance is ESR1 mutations. The first-generation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Downton, Teesha, Zhou, Fiona, Segara, Davendra, Jeselsohn, Rinath, Lim, Elgene
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9447452/ https://www.ncbi.nlm.nih.gov/pubmed/36081610 http://dx.doi.org/10.2147/DDDT.S380925

Ejemplares similares

The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance
por: Nardone, Agostina, et al.
Publicado: (2018)

CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective
por: Zhou, Fiona H., et al.
Publicado: (2023)

Effect of a brain‐penetrant selective estrogen receptor degrader (SERD) on binge drinking in female mice
por: Chen, Hu, et al.
Publicado: (2022)

ZB716, a steroidal selective estrogen receptor degrader (SERD), is orally efficacious in blocking tumor growth in mouse xenograft models
por: Guo, Shanchun, et al.
Publicado: (2018)

Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective
por: Hernando, Cristina, et al.
Publicado: (2021)

Metabolism, pharmacokinetics, and bioavailability of ZB716, a Steroidal Selective Estrogen Receptor Downregulator (SERD)
por: Zhang, Changde, et al.
Publicado: (2017)

Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer
por: Freelander, Allegra, et al.
Publicado: (2021)

Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
por: Pan, Mengwu, et al.
Publicado: (2023)

SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER + breast cancer models
por: Zhou, Feng, et al.
Publicado: (2023)

The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells
por: Fanning, Sean W, et al.
Publicado: (2018)

Effects of Endocrine Therapy on Cognitive Function in Patients with Breast Cancer: A Comprehensive Review
por: Haggstrom, Lucy R., et al.
Publicado: (2022)

The GBT-SerDes ASIC prototype
por: Moreira, P, et al.
Publicado: (2010)

High speed serdes devices and applications
por: Stauffer, David R, et al.
Publicado: (2008)

Phase 1 study of oral selective estrogen receptor degrader (SERD) amcenestrant (SAR439859), in Japanese women with ER-positive and HER2-negative advanced breast cancer (AMEERA-2)
por: Tamura, Kenji, et al.
Publicado: (2023)

The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options
por: Wang, Yating, et al.
Publicado: (2022)

How drug resistance takes shape
por: Jeselsohn, Rinath, et al.
Publicado: (2016)

ESR1 fusions and therapeutic resistance in metastatic breast cancer
por: Nagy, Zsuzsanna, et al.
Publicado: (2023)

Corrigendum: ESR1 fusions and therapeutic resistance in metastatic breast cancer
por: Nagy, Zsuzsanna, et al.
Publicado: (2023)

Breast Tumor Analysis Using Shifted-Excitation Raman Difference Spectroscopy (SERDS)
por: Gebrekidan, Medhanie Tesfay, et al.
Publicado: (2018)

The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
por: Grinshpun, Albert, et al.
Publicado: (2023)

Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor–positive Breast Cancer
por: Cheng, Yu-Chen, et al.
Publicado: (2023)

Accurate in vivo tumor detection using plasmonic-enhanced shifted-excitation Raman difference spectroscopy (SERDS)
por: Strobbia, Pietro, et al.
Publicado: (2021)

Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells
por: Dubash, Taronish D., et al.
Publicado: (2023)

Estrogen-regulated feedback loop limits the efficacy of estrogen receptor–targeted breast cancer therapy
por: Xiao, Tengfei, et al.
Publicado: (2018)

Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
por: Hopcroft, Lorna, et al.
Publicado: (2023)

RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models
por: Garner, Fiona, et al.
Publicado: (2015)

MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
por: Portman, Neil, et al.
Publicado: (2020)

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
por: Hopcroft, Lorna, et al.
Publicado: (2023)

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
por: Hopcroft, Lorna, et al.
Publicado: (2023)

Estrogens in schizophrenia: progress, current challenges and opportunities
por: Brand, Bodyl A., et al.
Publicado: (2021)

Optimization of small molecule degraders and antagonists for targeting estrogen receptor based on breast cancer: current status and future
por: Yao, Jiaqi, et al.
Publicado: (2023)

A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer
por: Jhaveri, Komal, et al.
Publicado: (2021)

SAT-341 Pharmacology and Metabolism of GLL398 an Oral Selective Estrogen Receptor Degrader for Endocrine Therapy of Breast Cancer
por: Guo, Shanchun, et al.
Publicado: (2019)

Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, A Novel Oral Selective Estrogen Receptor Degrader, in Healthy Post-Menopausal Women
por: Conlan, Maureen G., et al.
Publicado: (2020)

Biomarkers for Immunotherapy of Oral Squamous Cell Carcinoma: Current Status and Challenges
por: Almangush, Alhadi, et al.
Publicado: (2021)

Current Status, Opportunities, and Challenges of Exosomes in Oral Cancer Diagnosis and Treatment
por: Liu, Hongyu, et al.
Publicado: (2022)

Correction to: Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, A Novel Oral Selective Estrogen Receptor Degrader, in Healthy Post-Menopausal Women
por: Conlan, Maureen G., et al.
Publicado: (2020)

The Tissue-Selective Estrogen Complex: A Review of Current Evidence
por: Pazhekattu, Rinu, et al.
Publicado: (2015)

Targeting the formation of estrogens for treatment of hormone dependent diseases–current status
por: Rižner, Tea Lanišnik, et al.
Publicado: (2023)

Messina: A Novel Analysis Tool to Identify Biologically Relevant Molecules in Disease
por: Pinese, Mark, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_24sfk2ncjl8pp1i93598mtpo3l